Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2026-04-02 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（商有光-已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Work Report" for the year 2025 of Northeast Pharmaceutical Group Co., Ltd. It details the independent director's activities, attendance at board and committee meetings, communication with auditors, and evaluation of company governance and operations during the year. The content focuses on the independent director's duties, oversight, and compliance with laws and regulations, rather than presenting financial statements or audit results. It is a detailed report on board/management oversight and director activities rather than a financial report or announcement. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2026-04-02 Chinese
关于公司2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2025 profit distribution plan, including details on cash dividends per share, total dividend amount, and related financial figures. It references the board meeting where the plan was approved and states that the plan will be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. The document length is short (2003 characters), and it is not a full annual or interim report, nor a regulatory filing or report publication announcement. Therefore, the appropriate classification is DIV with high confidence.
2026-04-02 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Audit Report / Information Classification · 85% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the fiscal year 2025, prepared by a company (东北制药集团股份有限公司). It contains accounting data such as beginning balances, cumulative amounts, interest, repayments, and ending balances for various related parties. The content is financial and operational in nature but does not represent a full annual or interim financial report. It is not an announcement or a brief summary but a detailed financial disclosure related to related party transactions. This type of detailed financial disclosure about related party transactions is typically part of management or audit disclosures but here it is presented as a standalone summary table. It does not fit the definitions of Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a regulatory announcement or certification. Given the detailed financial data and focus on related party transactions, the best fitting category is Audit Report / Information (AR), which includes applied accounting principles and related financial disclosures outside of full annual reports. FY 2025
2026-04-02 Chinese
关于召开公司2025年度股东会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the company's 2025 Annual General Meeting (AGM), including the meeting date, voting procedures, agenda items, and proxy voting instructions. It does not contain the actual annual report or financial statements but rather announces the meeting where such reports and proposals will be discussed and voted on. The document length is 4250 characters, which is relatively short and consistent with a meeting notice rather than a full report. The presence of agenda items such as the 2025 annual report and financial statements indicates this is a notice for the AGM, not the report itself. Therefore, the document fits the category of AGM Information (AGM-R).
2026-04-02 Chinese
2025年度独立董事述职报告（马海天）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 of a company. It details the independent director's personal background, attendance at board and shareholder meetings, participation in committees, communication with auditors, and overall evaluation of their duties during the year. It also references various board decisions and corporate governance activities. The content is a detailed report on the independent director's performance and activities over the year, not a general annual report or financial statement. This type of document fits best under Board/Management Information (MANG), as it relates to management and board-level disclosures about director activities and governance rather than financial results or regulatory filings. The document length and detail confirm it is a full report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2026-04-02 Chinese
关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in the company's accounting policies. It references the Ministry of Finance's new accounting standards and explains the impact of the change on the company's financials. It includes statements from the audit committee and the board of directors approving the change. The document is relatively short (1663 characters) and does not contain actual financial statements or detailed financial data. It is an announcement of a policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-02 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.